Selank is what calm looks like when a peptide quiets anxiety without dimming the mind.

The short version

Selank is a small lab-made peptide — a short chain of seven amino acids (a heptapeptide) — first built in Russia and studied there as an anti-anxiety (anxiolytic) and brain-supporting (nootropic) compound. The headline that keeps coming back is calm without the fog: in research and in user reports it seems to take the edge off anxiety while the mind stays clear and energy holds steady, which is the opposite of the heavy, sleepy feeling people link to older anti-anxiety drugs. In rats and small Russian human studies it eased anxiety, nudged the brain's calming GABA system, slowed the enzymes that break down the body's own feel-good peptides, and raised a growth factor tied to learning. Here is the honest part: Selank is not FDA-approved, almost all the human data comes from one country, and it is sold only as a research chemical. What people report — including the downsides — is on the effects page.

What the Selank research has actually measured

Across three decades of mostly Russian research, Selank (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, also called TP-7) has produced a consistent picture: an anxiolytic effect that arrives without the sedation, cognitive dulling, or dependence associated with classical calming drugs ^[6]. It is a synthetic, stabilized version of tuftsin — a natural four-amino-acid immune peptide your body cuts from an antibody — extended with a Pro-Gly-Pro tail so it survives longer in the body.

The mechanism is not a single switch. Selank acts as a positive allosteric modulator of GABA receptor binding — meaning it tunes up the brain's main calming channel from a side door rather than forcing it open like a benzodiazepine does — and it does so with a subtype-selective, concentration-dependent profile distinct from those drugs ^[1]. In rat frontal cortex a single 300 µg/kg dose shifted the expression of 45 genes at one hour and 22 at three hours, with the changes correlating positively with what GABA itself produces ^[4]. In human plasma it inhibited enkephalin-degrading enzymes with an IC50 around 15 µM, stabilizing the body's own anti-anxiety enkephalins ^[2]. This is the Selank research in one paragraph, and every number traces to a cited study.

Calm but clear — the effect people keep describing

The single most consistent community report is a softening of background anxiety that does not feel like being drugged or slowed down — the volume on anxious thoughts turned down while the mind stays sharp. That maps onto the research: in a Russian clinical study in generalized anxiety disorder, intranasal Selank produced an anxiolytic and mild activating effect comparable to a benzodiazepine comparator, but without sedation, cognitive impairment, or withdrawal ^[6]. A separate clinical study reported anxiolytic benefit and framed Selank as a way to optimize anxiety-disorder treatment ^[16].

Those are genuinely promising signals — and they sit on a thin base. The trials are small, almost entirely from Russian research groups, with limited independent Western replication, and Selank is not approved by the FDA or EMA. The honest, plain-English account of what people report — the upsides and the downsides — lives on Selank effects.

More than an anxiolytic: memory, mood, and the immune angle

Selank's research file reaches past anxiety. In rats it had an optimizing action on a conditioned active-avoidance reflex — a standard learning task — consistent with a nootropic effect ^[8], and it experimentally improved learning and memory performance ^[9]. Intranasal Selank also raised brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival and plasticity, in the rat hippocampus ^[3], which is a plausible thread connecting the peptide to its reported mental clarity.

Because it descends from tuftsin, an immune peptide, Selank also carries an immunomodulatory side. In patients with anxiety-asthenic disorders it shifted the Th1/Th2 cytokine balance and modulated IL-6, leading researchers to describe it as a novel immunomodulator alongside its calming action ^[5]. It is one of the few anxiolytics studied as much for the immune system as for the mind.

Honest about the gaps

The optimism here is about a research direction, not a settled verdict. Most efficacy data are preclinical (rodent) or come from small clinical studies, and human evidence is far thinner than for approved anxiolytics. The pharmacokinetics of intact Selank in people are poorly characterized in mainstream literature — the intact peptide is short-lived, on the order of minutes, with active metabolites proposed (but not rigorously quantified) to extend the effect. Selank is not FDA-approved, is sold strictly as a research chemical, and is not intended for human use. This site is an editorial digest of that literature — it documents what the studies measured and where the open questions are. Start with Selank effects, the mechanism in Selank research, or the full source list in the Selank references.